Skip to content Skip to footer

ISSN 1933-0863 (PRINT) ISSN 1933-0871 (ONLINE)

Menu
Menu

Home

Main menu

Trending

Latest Issue

Articles
Urine C-reactive protein content and non-invasive molecular grading of renal cell carcinoma
Introduction Renal cell carcinoma (RCC) accounts for 4.2% of adult malignancies and is the 10th leading cause of cancer deaths in the United States.1 In the United States in 2024, more than 81,000 new cases were diagnosed and more than 14,300 died, due…
March 16, 2019
Articles
Practice-Ready Molecular Imaging in Renal Cell Carcinoma
Abstract : BACKGROUND: Renal cell carcinoma (RCC) is the most common kidney malignancy, often associated with poor prognosis due to late-stage diagnosis and metastasis. Recent research has identified PIWI-interacting RNAs (piRNAs) and PIWI-like proteins as potential biomarkers and therapeutic targets in cancer,…
February 20, 2026
Articles
The New Frontier: Advancements in Kidney Cancer Treatment
Thomas E. Hutson, DO, PharmD Texas Tech University Health Science Center School of Medicine Lubbock, Texas 79415 Correspondence to: Thomas Hutson, DO, PharmD Dear colleagues, The landscape of kidney cancer treatment is in a state of rapid and thrilling evolution. As editors,…
February 20, 2026
Articles
Kidney Cancer Summary from ASCO 2025: Therapies, Biomarkers, and Beyond
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial Citation: Zhou A, et al. Lancet Oncology. 2025 Sep;26(9):1145–1157. Methods: ETER100 was a multicentre, randomised, open-label, phase 3 trial at 37 sites in China. Patients aged…
February 20, 2026
Articles
The Future of RCC Treatment
Thomas E. Hutson, DO, PharmD Texas Tech University Health Science Center School of Medicine Lubbock, Texas 79415 Correspondence to: Thomas Hutson, DO, PharmD The Kidney Cancer Journal is pleased to receive and review the expert consensus manuscript stemming from the IKCSEU24 Think…
February 21, 2026

Current Trends

ASCO 2026 Annual Meeting: Kidney Cancer: Clinical and Research Highlights
Articles
doi.org/10.52733/ASCO26Summary Thomas E. Hutson, DO, PharmD, FACP Editor-in-Chief, Kidney Cancer Journal A Summary Report for the Global Oncology Community Chicago, Illinois  |  May 29 – June 2, 2026  |  Kidney Cancer Journal, Volume 24…
Most Clinically Significant Kidney Cancer Presentations from ASCO 2026
Articles Latest Updates
Selected by the Editor-in-Chief | Kidney Cancer Journal, Volume 24(2) Primary data drawn from ASCO 2026 presentations, JCO supplement abstracts, press releases, and peer-reviewed commentary. Abstract 1 — LBA418 LITESPARK-022: Pembrolizumab Plus Belzutifan Versus Pembrolizumab Plus Placebo as Adjuvant Therapy for Clear…
Renal Cell Carcinoma at the ASCO 2026 Inflection Point -Pre-meeting Preview
Articles Latest Issue new blog
May 29–June 2, 2026 | Chicago, IL Senthil Pazhanisamy, BPharma, MS, PhD. Overview The 2026 ASCO Annual Meeting arrives at a critical inflection point for renal cell carcinoma (RCC). The February ASCO GU Symposium in San Francisco delivered a rapid sequence of…

Explore Our New Articles